Our stable recombinant AequoScreen cell lines express a variety of GPCRs which all couple to a calcium response. Upon GPCR stimulation and subsequent calcium binding to the aequorin oxidation of coelenterazine leads to emission of light.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
You successfully added item(s) to your cart
This product contains living cells. Some cells may be restricted for sale in specified countries. Please inquire at your local sales office for more information.
AequoScreen® Double Transfected Cell Lines: Adrenergic, alpha 2A subtype. Human Recombinant, in HEK293 host cell. Two vials of cryopreserved cells are shipped per order. A detailed technical dossier includes sequence, culture conditions and pharmacological properties of the recombinant receptor. All cell lines are tested for the absence of mycoplasma. Terms and conditions apply. Some products are not available in some countries. Please inquire at your local sales office for more information.
The AequoScreen technology is a generic GPCR technology which can be used with Gs, Gi and Gq coupled GPCRs and calcium coupled ion channels. Following receptor stimulation, increases in intracellular calcium enable measurement of the resulting flash luminescence signal.
|Assay Target Class||GPCR|
|Assay Target Type||Cell line|
|Assay Validated||Calcium Luminescence, Binding, Calcium Fluorescence|
|G-Alpha Coupling Protein||Ga16|
|G-Alpha Natural Receptor||Gs|
|Product Brand Name||AequoScreen|
|Second Messenger Release||Calcium flux|
|Shipping Condition||Dry Ice|
|Therapeutic Area||Central Nervous System, Pain, Cardiovascular, Inflammation|
|Unit Size||5 million cells|
PerkinElmer’s validated, ready-to-use AequoZen™or cAMPZen™ frozen, irradiated cells make it easier for you to perform functional testing of GPCRs. Just thaw and use! Reliable, convenient AequoZen cells for aequorin calcium testing or cAMPZen cells for cAMP testing let you get the testing done. So you can concentrate on results.
G protein coupled receptors (GPCRs) have been considered as a highly “druggable” target for many years, with over 40% of marketed drugs acting to modulate their function. For many years, radiometric techniques have dominated GPCR screening. However in the last decade the development of functional assays, where the effect of molecules is evaluated in terms of GPCR activation, has accelerated.In particular, measurement of calcium signaling and the development of molecular strategies which couple the majority of GPCRs to calcium signaling has allowed the use of high-throughput functional screening in GPCR research.